Types of Peptides Explained
The word "peptides" is often used as if it describes a single thing — a category with shared properties and a unified evidence base. In reality, it describes hundreds of different molecules with vastly different mechanisms, uses, evidence levels, and regulatory statuses. Understanding this diversity is essential before evaluating any specific peptide or protocol.
This guide maps the major categories of therapeutic peptides currently in use, what each is broadly used for, what the evidence actually shows, and where each sits legally. The goal is to give you an honest framework for understanding what you're reading about — and what questions to ask if you're considering speaking to a clinician.
Key Takeaways
- Peptides span six major therapeutic categories with very different evidence profiles.
- GLP-1 receptor agonists (semaglutide, tirzepatide) have the strongest evidence base, backed by large randomised controlled trials.
- Growth hormone secretagogues and repair peptides like BPC-157 have promising preclinical data but limited large-scale human trials.
- Regulatory status varies widely — some peptides are FDA-approved drugs, others are compounded with a prescription, and others are sold as research chemicals.
- Evidence level and regulatory status are not the same thing — always assess both independently.
How to Read This Guide
Each category below includes an evidence bar — a visual indicator of where the current human evidence sits, from strong (multiple large randomised controlled trials) to early (animal models or small human studies only). This is not a judgment of whether a peptide "works" — it reflects the current state of published research and should guide how much confidence you place in any claims made about it.
Regulatory badges indicate each peptide's current legal status in the United States:
Category 1: GLP-1 Receptor Agonists
Weight Loss & Metabolic Health
Strongest EvidenceWhat they are: GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally produces after eating. GLP-1 receptor agonists are synthetic peptides that mimic this hormone, binding to GLP-1 receptors throughout the body to regulate appetite, blood sugar, and metabolism.
Key examples:
How they work: They bind to GLP-1 receptors in the pancreas (stimulating insulin release), the gut (slowing gastric emptying), and the brain (reducing appetite and increasing feelings of fullness). Tirzepatide also acts on GIP receptors, providing a dual mechanism.[1]
Who they're used for: Adults with type 2 diabetes, obesity (BMI ≥30), or overweight with at least one weight-related condition. Semaglutide also has FDA approval for cardiovascular risk reduction in adults with established heart disease who are overweight or obese.
What to know: This is the most robustly evidenced category of therapeutic peptides. Multiple large randomised controlled trials have demonstrated significant and sustained weight loss, improved glycaemic control, and cardiovascular benefits. These are pharmaceutical drugs, not supplements — they require a prescription and medical oversight.
Category 2: Growth Hormone Secretagogues
Growth Hormone, Muscle & Body Composition
Moderate EvidenceWhat they are: Growth hormone secretagogues (GHS) are peptides that stimulate the pituitary gland to produce and release more of its own growth hormone — rather than introducing growth hormone directly. This is a meaningful distinction: they work with the body's natural regulatory system rather than bypassing it.
Key examples:
*Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy; its use in general longevity or body composition is off-label.
How they work: These peptides bind to growth hormone-releasing hormone (GHRH) receptors or ghrelin receptors in the pituitary gland, triggering a pulse of natural growth hormone release. This in turn elevates IGF-1 (insulin-like growth factor 1), which promotes muscle protein synthesis, fat metabolism, and tissue repair.[2]
Who they're used for: Clinically, adults with documented growth hormone deficiency. Off-label, they are widely used in longevity medicine and body recomposition. CJC-1295 and Ipamorelin are frequently prescribed together for synergistic effect.
What to know: There is genuine clinical utility here, particularly for adult growth hormone deficiency. Evidence for off-label longevity and body composition use is more limited, consisting of smaller studies and significant anecdotal data. Importantly, because growth hormone secretagogues stimulate cell growth pathways, they are contraindicated in people with active cancer or a strong personal or family history of cancer. They are prohibited by the World Anti-Doping Agency (WADA) in competitive sport.[3]
Category 3: Repair & Recovery Peptides
Tissue Healing, Injury Recovery & Inflammation
Limited Human EvidenceWhat they are: A group of peptides that promote tissue repair, reduce inflammation, and accelerate recovery from injury. This is one of the most discussed categories in wellness and sports medicine, and also one where the evidence gap between preclinical (animal) and human data is widest.
Key examples:
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide originally derived from human gastric juice. Animal studies have consistently shown accelerated healing of tendons, ligaments, muscle, and gastrointestinal tissue, along with anti-inflammatory and angiogenic effects. A case series of 17 patients reported symptom improvement in over 90% of participants following BPC-157 injections for tendon and ligament injuries — but this is a very small, preliminary study. Large-scale human randomised controlled trials do not yet exist.[4]
TB-500 is a synthetic fragment of thymosin beta-4, a protein the body naturally upregulates in response to tissue injury. Preclinical and veterinary data suggest benefits for tendon, muscle, and connective tissue repair, along with anti-inflammatory activity. Human trial data is currently very limited.
GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring copper-binding peptide involved in skin and connective tissue remodelling. It has a broader evidence base than BPC-157 and TB-500 for topical dermatological use, and is increasingly explored for orthopaedic applications.[2]
What to know: The anecdotal base for BPC-157 and TB-500 is very large, and reported side effects in that anecdotal base appear generally mild. However, the theoretical risk that angiogenic and pro-growth peptides could accelerate dormant tumour growth has been raised in the literature and should be taken seriously. Both BPC-157 and TB-500 are prohibited by WADA in competitive sport. Neither is FDA-approved for human use.
Category 4: Hormone & Fertility Peptides
Hormonal Regulation, Sexual Health & Fertility
Mixed EvidenceWhat they are: Peptides that interact with the hormonal and reproductive system — either as naturally occurring hormones used therapeutically, or as synthetic analogues targeting the same pathways.
Key examples:
Oxytocin is a naturally occurring peptide hormone produced by the hypothalamus. It has long been used medically to induce labour and manage postpartum haemorrhage. It is also being explored in research for its potential role in social bonding, anxiety, and metabolic health — though human evidence for these off-label uses remains early-stage.
PT-141 (Bremelanotide) is FDA-approved for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women under the brand name Vyleesi. It works through melanocortin receptors in the central nervous system rather than the vascular system, distinguishing it from treatments like Viagra.[5]
Gonadorelin is a synthetic version of gonadotropin-releasing hormone (GnRH). It is commonly prescribed alongside testosterone replacement therapy (TRT) in men to preserve testicular function and fertility during treatment.
What to know: This category ranges from well-characterised FDA-approved drugs to very early-stage research compounds. The evidence base is highly peptide-specific — what is known about oxytocin does not translate to kisspeptin, and vice versa. As with all hormone-related interventions, medical oversight and baseline lab work are essential.
Category 5: Skin & Collagen Peptides
Skin Health, Collagen & Anti-Aging (Topical)
Moderate EvidenceWhat they are: Peptides applied topically or taken orally to support skin structure, collagen production, and the visible signs of aging. This is the most commercially widespread category of peptides and includes the vast majority of peptides found in skincare products and over-the-counter supplements.
Key examples:
Collagen peptides are hydrolysed fragments of collagen protein that are small enough to be absorbed through the gut. Multiple randomised controlled trials have demonstrated modest but consistent improvements in skin hydration, elasticity, and the appearance of fine lines with regular oral supplementation.[6] The evidence base here is meaningfully stronger than most non-GLP-1 peptide categories.
GHK-Cu applied topically stimulates fibroblast activity and collagen synthesis, and has been studied in dermatology for wound healing and cosmetic anti-aging applications. Evidence supports genuine but modest effects on skin quality when used consistently.
What to know: This is the safest and most accessible category of peptides — most are available over the counter as supplements or skincare ingredients. The effects are real but generally modest and require consistent long-term use. They are not substitutes for more targeted medical interventions and should not be confused with therapeutic peptides administered by injection.
Category 6: Longevity & Cellular Health Peptides
Longevity, Cellular Repair & Anti-Aging
Early EvidenceWhat they are: A group of peptides being explored for their potential to slow cellular aging, support immune function, and improve markers of biological longevity. This is the most speculative category, where the gap between commercial claims and scientific evidence is largest.
Key examples:
Epitalon is a synthetic tetrapeptide derived from the pineal gland's epithalamin. Animal and in vitro studies suggest it may activate telomerase (the enzyme that maintains telomere length) and exert anti-aging effects at the cellular level. Human studies are very limited in scale and largely from Russian research institutions, where many of these compounds were originally developed.[7]
Thymosin Alpha-1 has been studied in multiple randomised controlled trials for its immune-modulating effects, particularly in the context of sepsis and certain cancers. A recent meta-analysis suggested potential benefits for immune function, though large confirmatory trials have produced mixed results. It has approval in some countries (though not the US) for chronic hepatitis B and C.
Selank and Semax are neuropeptides developed in Russia and used clinically there for anxiety and cognitive support. They work on BDNF (brain-derived neurotrophic factor) pathways. Neither has been evaluated in large Western randomised controlled trials.
What to know: The compounds in this category are being promoted heavily in longevity and biohacking communities, often with claims that significantly outpace the existing evidence. This does not mean they are ineffective — it means the rigorous human evidence needed to know is largely not yet available. Most are sold as research chemicals, not pharmaceutical-grade products, which carries additional quality and safety risks.
Quick Reference: Evidence and Regulatory Summary
| Category | Key Examples | Evidence Level | US Status |
|---|---|---|---|
| GLP-1 Agonists | Semaglutide, Tirzepatide | Strong — large RCTs | FDA Approved |
| GH Secretagogues | Sermorelin, Ipamorelin, CJC-1295 | Moderate — smaller studies | Compounded |
| Repair Peptides | BPC-157, TB-500, GHK-Cu | Limited — animal data | Research Grade |
| Hormone / Fertility | PT-141, Gonadorelin, Oxytocin | Mixed — varies by peptide | FDA Approved / Compounded |
| Skin / Collagen | Collagen peptides, GHK-Cu topical | Moderate — multiple RCTs | OTC Supplement / Cosmetic |
| Longevity | Epitalon, Thymosin Alpha-1 | Early — in vitro / animal | Research Grade |
An Honest Note on the Evidence Landscape
The peptide space is characterised by a significant asymmetry between commercial enthusiasm and scientific evidence. GLP-1 agonists are genuinely transformative drugs with some of the most impressive trial data in recent pharmaceutical history. Most other therapeutic peptides are nowhere near that standard of evidence — and being honest about that distinction is important.[8]
This does not mean the other categories are necessarily ineffective. Many have compelling mechanistic rationales and strong preclinical signals. It means that extrapolating animal study results to human benefit is not a reliable process, and that the people currently using many of these compounds — however optimistic the anecdotal reports — are doing so ahead of the definitive human evidence.
For anyone considering peptide therapy beyond GLP-1 agonists, the most important thing is to work with a clinician who can assess your individual situation, order appropriate labs, source pharmaceutical-grade compounds through regulated channels, and monitor for both benefit and adverse effects. Self-administering research-grade peptides without this context is not a recommended approach.
Not sure which category applies to your goals?
Our free quiz helps match your health profile and objectives to the most relevant options — so you can have a more informed conversation with a clinician.
Take Our Peptide Plan Quiz →References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989–1002. Available from: https://pubmed.ncbi.nlm.nih.gov/33567185/
- Demopoulos N, et al. Therapeutic Peptides in Orthopaedics. PMC. 2025. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12753158/
- World Anti-Doping Agency. Prohibited List. WADA. Available from: https://www.wada-ama.org/en/prohibited-list
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Curr Pharm Des. 2011. Available from: https://pubmed.ncbi.nlm.nih.gov/20946119/
- U.S. Food & Drug Administration. FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women. 2019. Available from: https://www.fda.gov
- Proksch E, et al. Oral supplementation of specific collagen peptides has beneficial effects on human skin physiology. Skin Pharmacol Physiol. 2014;27(1):47–55. Available from: https://pubmed.ncbi.nlm.nih.gov/23949208/
- Atria Health. Peptides for Longevity: Evidence Review. 2024. Available from: https://www.atria.org/education/peptides-for-longevity/
- Topol E. The Peptide Craze. Ground Truths. 2025. Available from: https://erictopol.substack.com/p/the-peptide-craze